IL28B Polymorphism Correlates with Active Hepatitis in Patients with HBeAg-Negative Chronic Hepatitis B

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Lee, I Cheng ^a,b   Lin, Chen Hao ^a,b   Huang, Yi Hsiang ^a,b   Huo, Teh Ia ^a,b   Su, Chien Wei ^a,b   Hou, Ming Chih ^a   Huang, Hui Chun ^a   Lee, Kuei Chuan ^a,b   Chan, Che Chang ^a,b   Lin, Ming Wei ^b   Lin, Han Chieh ^a   Lee, Shou Dong ^c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHENG HSIN GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 28B; VIRUS DNA;

ADULT; ARTICLE; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS B; HUMAN; INTERLEUKIN 28B GENE; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD;

ADULT; FEMALE; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; VIRAL LOAD;

EID: 84874575857     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058071     Document Type: Article

References (43)

1. Lavanchy D, (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11: 97-107.
2. Ganem D, Prince AM, (2004) Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 350: 1118-1129.
3. Liaw YF, Chu CM, (2009) Hepatitis B virus infection. Lancet 373: 582-592.
4. Liaw YF, (2009) Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 29 (Suppl 1): 100-107.
5. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, et al. (2008) Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 100: 1134-1143.
6. Huang YH, Wu JC, Chang TT, Sheen IJ, Huo TI, et al. (2006) Association of core promoter/precore mutations and viral load in e antigen-negative chronic hepatitis B patients. J Viral Hepat 13: 336-342.
7. Lee IC, Huang YH, Chan CC, Huo TI, Chu CJ, et al. (2011) Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis B. Clin Nutr. 30: 647-652.
8. Perrillo R, (2009) Benefits and risks of interferon therapy for hepatitis B. Hepatology. 49: S103-111.
9. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-801.
10. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
11. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104.
12. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 41: 1105-1109.
13. Balagopal A, Thomas DL, Thio CL, (2010) IL28B and the control of hepatitis C virus infection. Gastroenterology 139: 1865-1876.
14. Beinhardt S, Aberle JH, Strasser M, Dulic-Lakovic E, Maieron A, et al. (2012) Serum Level of IP-10 Increases Predictive Value of IL28B Polymorphisms for Spontaneous Clearance of Acute HCV Infection. Gastroenterology 142: 78-85 e72.
15. Lok AS, McMahon BJ, (2009) Chronic hepatitis B: update 2009. Hepatology 50: 661-662.
16. European Association For The Study Of The L, (2012) EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57: 167-85.
17. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, et al. (2008) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2: 263-283.
18. Yu ML, Huang CF, Huang JF, Chang NC, Yang JF, et al. (2011) Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 53: 7-13.
19. Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, et al. (2011) IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One 6: e18322.
20. Rao HY, Sun DG, Jiang D, Yang RF, Guo F, et al. (2012) IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat 19: 173-181.
21. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, et al. (2010) A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 139: 1586-1592, 1592 e1581.
22. Huang YH, Wu JC, Chang TT, Sheen IJ, Lee PC, et al. (2003) Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan. J Viral Hepat 10: 277-284.
23. Wursthorn K, Jaroszewicz J, Zacher BJ, Darnedde M, Raupach R, et al. (2011) Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. J Clin Virol 50: 292-296.
24. Barrett JC, Fry B, Maller J, Daly MJ, (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
25. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, et al. (2010) A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology. 52: 1232-1241.
26. Liaw YF, (2011) Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 53: 2121-2129.
27. Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, et al. (2010) Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 52: 508-513.
28. Tan AT, Koh S, Goh W, Zhe HY, Gehring AJ, et al. (2010) A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J Hepatol. 52: 330-339.
29. Jaroszewicz J, Ho H, Markova A, Deterding K, Wursthorn K, et al. (2011) Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antivir Ther 16: 915-924.
30. Chu CJ, Hussain M, Lok AS, (2002) Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology. 122: 1756-1762.
31. Lin CL, Kao JH, (2011) The clinical implications of hepatitis B virus genotype: Recent advances. J Gastroenterol Hepatol 26 (Suppl 1): 123-130.
32. Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, et al. (2003) Prevalence of HBV precore/core promoter variants in the United States. Hepatology 38: 619-628.
33. Yotsuyanagi H, Hino K, Tomita E, Toyoda J, Yasuda K, et al. (2002) Precore and core promoter mutations, hepatitis B virus DNA levels and progressive liver injury in chronic hepatitis B. J Hepatol. 37: 355-363.
34. Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, et al. (2012) Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B. Gastroenterology 142: 513-520 e511.
35. Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, et al. (2010) IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. The Journal of infectious diseases 202: 1749-1753.
36. Peng LJ, Guo JS, Zhang Z, Shi H, Wang J, et al. (2012) IL28B rs12979860 polymorphism does not influence outcomes of hepatitis B virus infection. Tissue Antigens 79: 302-305.
37. Li W, Jiang Y, Jin Q, Shi X, Jin J, et al. (2011) Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int 31: 1118-1126.
38. Ren S, Lu J, Du X, Huang Y, Ma L, et al. (2012) Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. Cancer immunology, immunotherapy 61: 1433-1439.
39. Wu X, Xin Z, Zhu X, Pan L, Li Z, et al. (2012) Evaluation of susceptibility locus for response to interferon-alpha based therapy in chronic hepatitis B patients in Chinese. Antiviral research 93: 297-300.
40. Lampertico P, Vigano M, Cheroni C, Facchetti F, Invernizzi F, et al. (2012) IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg-negative patients with chronic hepatitis B. Hepatology doi: 10.1002/hep.25749. [Epub ahead of print].
41. Pharm DT, Charlton M, Goldstein DB, (2012) Introduction to the genetics and biology of IL28B. Hepatology 56: 361-6.
42. Morrow MP, Pankhong P, Laddy DJ, Schoenly KA, Yan J, et al. (2009) Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 113: 5868-5877.
43. Lagging M, Askarieh G, Negro F, Bibert S, Soderholm J, et al. (2011) Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One 6: e17232.